IL33 and neoplasm: We found that the additional administration of recombinant murine IL-33 to mice treated with 5-FU led to a more significant delay in tumor growth (Figure 8F), prolonged survival (Figure 8G), and increased cleaved-caspase 3 (Figure S7B) than those observed in control mice or mice receiving either rmIL-33 or 5-FU alone.